News
Evolva publishes timeline of the Reverse Stock Split
Evolva publishes timeline of the Reverse Stock Split
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
EQS-News: BB BIOTECH AG: Lackluster first quarter for biotech stocks
Annual General Meeting – Shareholders approve all proposals of the Board of Directors
Annual General Meeting – Shareholders approve all proposals of the Board of Directors
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Evolva shareholders approve all motions proposed by the Board at today’s Annual General Meeting
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Executive Leadership Team Change
Relief Therapeutics Announces Executive Leadership Team Change
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Holding SA to Hold Extraordinary General Meeting of Shareholders
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Relief Therapeutics Appoints World-Renowned Gene Therapy Pioneer Guangping Gao, Ph.D. as Chair of Scientific Advisory Board
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Launches Share Buyback Program of up to CHF 2 Billion
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports
Evolva publishes agenda for 2023 Annual General Meeting
Evolva publishes agenda for 2023 Annual General Meeting
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
EQS-News: Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.85 per share
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Relief Therapeutics Announces Availability of New PKU GOLIKE BARs in Europe
Kuros Biosciences reports results for the full year 2022
Kuros Biosciences reports results for the full year 2022
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™
Relief Therapeutics Provides Update From Collaboration Partner on OLPRUVA™
Evolva delivers accelerated revenue growth of 57% in 2022 and substantially improved profitability profile
Evolva delivers accelerated revenue growth of 57% in 2022 and substantially improved profitability profile
Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative
Evolva partners with Grace Breeding to replace chemical fertilizers with nature-based alternative
